NVIDIA is joining with Schrödinger to further expand the speed and accuracy of its computational platform; collaborating with AstraZeneca to develop a transformer-based generative AI model for chemical structures; and teaming up with UF Health, the University of Florida (UF)’s academic health center, to apply what the partners say is the largest clinical language model developed to date for drug discovery as well as clinical medicine . . .
From Model to Molecule: NVIDIA Doubles Down on AI Drug Discovery
GPU inventor partners with Schrödinger, AstraZeneca, UF Health on computational approaches to therapy development
NVIDIA plans to optimize Schrödinger’s FEP+ platform, designed to model and predict the properties of novel molecules, for the NVIDIA DGX SuperPOD™ system (pictured), in an expansion of an existing partnership designed to further accelerate Schrödinger’s drug discovery workflow. [NVIDIA]